Sarfez Pharmaceuticals
Sarfez Pharmaceuticals is a cardiovascular specialty company dedicated to improving existing drugs through innovative technologies and clinical experiences. They focus on developing safer and better medications for heart failure, kidney diseases, and uncontrolled hypertension, with an emphasis on affordability and price transparency. Their mission involves leveraging advanced drug delivery systems, clinical expertise, and strategic collaborations to enhance patient outcomes and reduce healthcare costs.
Industries
Nr. of Employees
small (1-50)
Sarfez Pharmaceuticals
Patents
Products
Torsemide extended-release tablets (loop diuretic)
Oral torsemide tablets formulated as an extended-release loop diuretic for treatment of edema associated with heart failure and renal disease; dosing guidance and safety information provided in prescribing information.
SOAANZ (torsemide) tablets
SOAANZ is a loop diuretic indicated in adults for the treatment of edema associated with heart failure or renal disease. It is available in oral tablet form with strengths of 20 mg, 40 mg, and 60 mg.
Rapid-action Orally-disintegrating Technology (ROTEC)
Technology platform for orally-disintegrating drugs that act quickly for rapid relief.
Self Emulsifying Drug Delivery System (SEEDS)
Drug delivery system for poorly permeable and extensively metabolized drugs taken in large dosages.
Matrix-based Extended Release (MEXFOR)
Extended release technology platform for drugs with short duration of action that need to be taken more than once a day.
Torsemide extended-release tablets (loop diuretic)
Oral torsemide tablets formulated as an extended-release loop diuretic for treatment of edema associated with heart failure and renal disease; dosing guidance and safety information provided in prescribing information.
SOAANZ (torsemide) tablets
SOAANZ is a loop diuretic indicated in adults for the treatment of edema associated with heart failure or renal disease. It is available in oral tablet form with strengths of 20 mg, 40 mg, and 60 mg.
Rapid-action Orally-disintegrating Technology (ROTEC)
Technology platform for orally-disintegrating drugs that act quickly for rapid relief.
Self Emulsifying Drug Delivery System (SEEDS)
Drug delivery system for poorly permeable and extensively metabolized drugs taken in large dosages.
Matrix-based Extended Release (MEXFOR)
Extended release technology platform for drugs with short duration of action that need to be taken more than once a day.
Services
Development and licensing of formulation platforms for extended-release, orally-disintegrating and self-emulsifying oral products to improve pharmacokinetics and bioavailability.
Protocol development, clinical trial design, data interpretation and management of regulatory submissions including interactions with regulatory authorities.
Management of sample requests for licensed practitioners and coordination with mail-order pharmacies to deliver product to patients.
Management of strategic alliances with specialized contract organizations and academic partners to enable a virtual, lower-cost development model.
Development and licensing of formulation platforms for extended-release, orally-disintegrating and self-emulsifying oral products to improve pharmacokinetics and bioavailability.
Protocol development, clinical trial design, data interpretation and management of regulatory submissions including interactions with regulatory authorities.
Management of sample requests for licensed practitioners and coordination with mail-order pharmacies to deliver product to patients.
Management of strategic alliances with specialized contract organizations and academic partners to enable a virtual, lower-cost development model.
Expertise Areas
- Formulation development and drug delivery
- Clinical trial management and protocol development
- Cardio-renal therapeutics (heart failure, kidney disease, hypertension)
- Regulatory compliance and FDA submissions
Key Technologies
- Matrix-based extended-release (MEXFOR)
- Orally-disintegrating tablet technology
- Self-emulsifying drug delivery systems (SEEDS)
- Oral solid/liquid and injectable dosage form development
News & Updates
A study on the impact of loop diuretic-induced overactive bladder in heart failure patients.
A study on bladder dysfunction and overactive bladder symptoms related to loop diuretics.
Research on the short duration of action of loop diuretics and its effect on salt loss and sodium retention.
A study on the impact of loop diuretic-induced overactive bladder in heart failure patients.
A study on bladder dysfunction and overactive bladder symptoms related to loop diuretics.
Research on the short duration of action of loop diuretics and its effect on salt loss and sodium retention.